Bastiaan Geelhoed
Overview
Explore the profile of Bastiaan Geelhoed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Camen S, Csengeri D, Geelhoed B, Niiranen T, Gianfagna F, Vishram-Nielsen J, et al.
J Am Heart Assoc
. 2022 Mar;
11(7):e024299.
PMID: 35322680
Background Although myocardial infarction (MI) and atrial fibrillation (AF) are frequent comorbidities and share common cardiovascular risk factors, the direction and strength of the association of the risk factors with...
12.
Himmelreich J, Harskamp R, Geelhoed B, Virdone S, Lucassen W, Gansevoort R, et al.
BMJ Open
. 2022 Feb;
12(2):e057476.
PMID: 35173009
Background: Advancing age is the primary selection criterion for community screening for atrial fibrillation (AF), with selection often restricted to those aged ≥65 years. If multivariable models were shown to...
13.
van Woerden G, Van Veldhuisen D, Gorter T, Ophuis B, Saucedo-Orozco H, van Empel V, et al.
ESC Heart Fail
. 2022 Feb;
9(2):953-957.
PMID: 35146949
Aims: Epicardial adipose tissue (EAT) is increasingly recognized as an important factor in the pathophysiology of heart failure (HF). Cardiac magnetic resonance (CMR) imaging is the gold-standard imaging modality to...
14.
Assum I, Krause J, Scheinhardt M, Muller C, Hammer E, Borschel C, et al.
Nat Commun
. 2022 Jan;
13(1):441.
PMID: 35064145
Genome-wide association studies (GWAS) for atrial fibrillation (AF) have uncovered numerous disease-associated variants. Their underlying molecular mechanisms, especially consequences for mRNA and protein expression remain largely elusive. Thus, refined multi-omics...
15.
Zwartkruis V, Geelhoed B, Suthahar N, Bakker S, Gansevoort R, Van Gelder I, et al.
Open Heart
. 2021 Dec;
8(2).
PMID: 34969833
Aims: It is unknown whether screen-detected atrial fibrillation (AF) carries cardiovascular risks similar to clinically detected AF. We aimed to compare clinical outcomes between individuals with screen-detected and clinically detected...
16.
Said F, Ter Maaten J, Martens P, Vernooy K, Meine M, Allaart C, et al.
J Clin Med
. 2021 Dec;
10(23).
PMID: 34884215
Introduction: Cardiac resynchronization therapy (CRT) is an established therapy for patients with heart failure with reduced ejection fraction (HFrEF). Women appear to respond differently to CRT, yet it remains unclear...
17.
Wouters P, Van Everdingen W, Vernooy K, Geelhoed B, Allaart C, Rienstra M, et al.
Eur Heart J Cardiovasc Imaging
. 2021 Dec;
23(12):1628-1635.
PMID: 34871385
Aims: Judicious patient selection for cardiac resynchronization therapy (CRT) may further enhance treatment response. Progress has been made by using improved markers of electrical dyssynchrony and mechanical discoordination, using QRSAREA,...
18.
Nguyen B, Crijns H, Tijssen J, Geelhoed B, Hobbelt A, Hemels M, et al.
Europace
. 2021 Nov;
24(6):910-920.
PMID: 34791160
Aims: The Routine vs. Aggressive risk factor driven upstream rhythm Control for prevention of Early persistent atrial fibrillation (AF) in heart failure (HF) (RACE 3) trial demonstrated that targeted therapy...
19.
Morseth B, Geelhoed B, Linneberg A, Johansson L, Kuulasmaa K, Salomaa V, et al.
Open Heart
. 2021 Aug;
8(2).
PMID: 34341095
Background: The main aim was to examine age-specific risk factor associations with incident atrial fibrillation (AF) and their attributable fraction in a large European cohort. Additionally, we aimed to examine...
20.
Al-Jazairi M, Nguyen B, De With R, Smit M, Weijs B, Hobbelt A, et al.
Europace
. 2021 Apr;
23(9):1359-1368.
PMID: 33899093
Aims: Maintaining sinus rhythm in patients with persistent atrial fibrillation (AF) is challenging. We explored the efficacy of class I and III antiarrhythmic drugs (AADs) in patients with persistent AF...